Travere Therapeutics
TVTX
136 hedge funds and large institutions have $901M invested in Travere Therapeutics in 2021 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 43 reducing their positions, and 36 closing their positions.
22% more call options, than puts
Call options by funds: $2.43M | Put options by funds: $1.99M
16% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.6% less ownership
Funds ownership: 103.98% → 101.37% (-2.6%)
9% less funds holding
Funds holding: 150 → 136 (-14)
39% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 36
42% less capital invested
Capital invested by funds: $1.56B → $901M (-$663M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$66.9M |
| 2 |
Goldman Sachs
New York
|
+$32.1M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$23.2M |
| 4 |
JP Morgan Chase
New York
|
+$20.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$20M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$40.2M |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$31.6M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$31.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$28.7M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.9M |
TVTX Hedge Fund Activity: Q2 2021 in Review
136 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2021, worth a combined $901M — down 42% from $1.56B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of TVTX and 22 opened new positions — a net loss of 14 holders — while 43 trimmed existing stakes and 50 added.
The largest buyer was Armistice Capital, adding an estimated $66.9M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $40.2M sold.
- 136 institutional investors held Travere Therapeutics (TVTX) as of Q2 2021, down from 150 in Q1 2021.
- Funds reported $901M of Travere Therapeutics stock for Q2 2021, down 42% quarter-over-quarter.
- 22 funds opened new Travere Therapeutics positions in Q2 2021 and 36 closed out, a net change of -14 holders.
- The largest Travere Therapeutics buyer in Q2 2021 was Armistice Capital, an estimated $66.9M added.
- The largest Travere Therapeutics seller in Q2 2021 was Point72 Asset Management, an estimated $40.2M sold.
Based on aggregated 13F filings for Q2 2021.